Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1723P_PR - Therapeutic nihilism or therapeutic realism: Perceptions of non-oncologist physicians regarding cancer patients’ prognosis

Date

16 Sep 2021

Session

ePoster Display

Topics

Survivorship;  Supportive and Palliative Care

Tumour Site

Presenters

Eoin O'Neill

Citation

Annals of Oncology (2021) 32 (suppl_5): S1175-S1198. 10.1016/annonc/annonc714

Authors

E. O'Neill1, D. Murphy2, C. Lyons1, R. Joyce1, C.G. Murphy3

Author affiliations

  • 1 Radiation Oncology, CUH - Cork University Hospital, T12 DFK4 - Cork/IE
  • 2 School Of Medicine, University College Cork, Cork/IE
  • 3 Department Of Medical Oncology, Bon Secours Hospital Cork, Cork/IE

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1723P_PR

Background

Typically, non-oncology physicians make the diagnosis of cancer and have initial discussions with patients during which questions regarding prognosis may be asked. According to Goldvaser et al., there is a lack of data on perception of cancer patients’ prognosis by non-oncology physicians. We conducted a survey among a group of Irish doctors working in medical and radiation oncology (“ONCs”, n=46) and doctors working in other areas including GPs and hospital specialties (“nonONCs”, n=301).

Methods

Participants were asked to estimate the 5-year survival of 12 common cancers (all stages combined), and also to estimate 5 year survival for 6 clinical scenarios (e.g. ‘a 47 year old woman with Stage 4 breast cancer’). Responses were compared to survival data from the National Cancer Registry of Ireland (NCRI), and between the two groups.

Results

When asked to estimate 5-year survival of common cancers with all stages combined, both ONCs and nonONCs underestimated survival of prostate cancer and melanoma, while nonONCs also underestimated survival of breast cancer, Hodgkin’s lymphoma and renal cancer. Both groups overestimated the survival of colorectal, lung, liver, gastric and pancreatic cancer. With regards to the clinical scenarios, both groups underestimated the survival of stage 3 colorectal cancer, stage 3 prostate cancer and stage 1 breast cancer, with significantly more pessimistic estimates by nonONCs (students t-test, p <0.005 in each case). Survival estimates did not differ significantly between the groups for lung cancer (stage 1 and stage 4) while nonONCs underestimated the survival of stage 4 breast cancer and were significantly more pessimistic than ONCs (p<0.005).

Conclusions

Both groups of doctors had difficulty estimating the survival of common cancers across combined stages, with ONCs estimating correctly in 4 of 12 cancers, and nonONCs in 2 of 12. The clinical scenarios showed that survival estimates are inaccurate even for defined stages among common malignancies such as breast, colorectal and prostate cancer, with greater pessimism among non-oncology doctors. Education of both oncology and non-oncology doctors is required to ensure patients are being counselled appropriately regarding prognosis.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.